# Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology
Canonical URL: https://biopharmsignal.com/news/AMRN/effects-of-icosapent-ethyl-on-risk-and-duration-of-hospitalizations-and-death-in-812cfc56
Ticker: AMRN
Company: Amarin Corporation
Source: Amarin Corporation
Published: 2026-03-02 13:00 EST
## Summary

Peer-reviewed paper indicates icosapent ethyl (IPE) was associated with fewer total hospitalizations and fewer days lost due to hospitalization and death,...

## Article Body
Peer-reviewed paper indicates icosapent ethyl (IPE) was associated with fewer total hospitalizations and fewer days lost due to hospitalization and death, providing additional insights on the effects of IPE on patient-centered measures of total disease burden

DUBLIN and BRIDGEWATER, N.J., March 02, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company committed to advancing the science of cardiovascular disease (CVD) worldwide, today highlighted recently published data in the European Journal of Preventive Cardiology showing in a post hoc analysis of the landmark REDUCE-IT study that, among statin-treated participants with elevated triglycerides and known CVD or with diabetes and other risk factors, patients treated with VASCEPA ® /VAZKEPA ® (icosapent ethyl) (IPE) experienced fewer total hospitalizations and fewer days lost due to hospitalization and death, providing additional insights on the effects of IPE on patient-centered measures of total disease burden. i

The analysis evaluated 8,179 participants randomized to receive either IPE 2 g twice daily or placebo and followed for a median of five years and determined if treatment with IPE would decrease the frequency and duration of hospitalizations.

Commenting on the published findings, Deepak L. Bhatt, MD, MPH, MBA, Director of the Mount Sinai Fuster Heart Hospital at the Icahn School of Medicine at Mount Sinai in New York, said, ”What stands out most in this analysis is the real-world relevance for patients and their families. Fewer hospitalizations can make a meaningful difference in daily life - allowing people to maintain independence and spend more time at home. These findings extend the benefits of treatment with IPE beyond cardiovascular prevention to potentially reduce the burden of hospitalizations and increase the chances of an individual living without hospitalization."

Lead author Michael Szarek, PhD, Mount Sinai Fuster Heart Hospital at the Icahn School of Medicine at Mount Sinai in New York and University of Colorado Anschutz Medical Campus, Aurora, CO, added: “For patients already managing heart disease or diabetes, every day outside the hospital matters. In this high-risk population, we saw reductions not only in how often individuals were hospitalized, but also in how much time they lost to being in the hospital or from premature death. These patient focused outcomes reinforce that IPE may help people spend more time living their lives and less time receiving acute medical care - a result with great significance for patients, their families, and the healthcare system at large.”

Data from REDUCE-IT have consistently shown robust relative and absolute risk reductions in the primary analyses and several sub-group analyses, which led to incorporation of IPE in multiple guidelines and consensus statements globally. ii

About the Analysis In this post hoc analysis of REDUCE-IT, investigators quantified the effects of IPE on total hospitalizations and days lost to hospitalization and death.

Among 8,179 statin-treated REDUCE-IT patients with established cardiovascular disease or age ≥50 years with diabetes and ≥1 additional risk factor, fasting triglyceride 1.69-5.63 mmol/L (135-499 mg/dL), and low-density lipoprotein cholesterol 1.06-2.59 mmol/L (41-100 mg/dL), total hospitalizations were analyzed with a competing risks marginal model for total events. The likelihood of no days lost to hospitalization and death and the rate of days lost among those who were hospitalized or died during the study were analyzed with a zero-inflated Poisson regression model. During a median 5.0 years of follow-up, IPE treatment was associated with fewer total hospitalizations (HR (95% CI) = 0.91 (0.84, 0.98), P = 0.017). Participants randomized to IPE were more likely to survive until the end of the study without hospitalization (OR (95% CI) = 1.12 (1.02, 1.22), P = 0.016) and had fewer days lost among those who were hospitalized or died (RR (95% CI) = 0.93 (0.93, 0.94), P 1% more frequent than placebo): arthralgia (2% vs 1%) and oropharyngeal pain (1% vs 0.3%).

Adverse events may be reported by calling 1-855-VASCEPA or the FDA at 1-800-FDA-1088.

Patients receiving VASCEPA and concomitant anticoagulants and/or anti-platelet agents should be monitored for bleeding.

FULL U.S. FDA-APPROVED VASCEPA PRESCRIBING INFORMATION CAN BE FOUND AT WWW.VASCEPA.COM

Europe For further information about the Summary of Product Characteristics (SmPC) for VAZKEPA ® in Europe, please visit: https://www.ema.europa.eu/en/documents/product-information/vazkepa-epar-product-information_en.pdf

Globally, prescribing information varies; refer to the individual country product label for complete information.

Forward-Looking Statements This press release contains forward-looking statements which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including beliefs about Amarin’s key achievements in 2024 and the potential impact and outlook for achievements in 2025 and beyond; Amarin’s 2025 financial outlook and cash position; Amarin’s overall efforts to expand access and reimbursement to VAZKEPA across global markets; expectations regarding potential strategic collaboration and licensing agreements with third parties, including our ability to attract additional collaborators, as well as our plans and strategies for entering into potential strategic collaboration and licensing agreements and the overall potential and future success of VASCEPA/VAZKEPA and Amarin that are based on the beliefs and assumptions and information currently available to Amarin.

All statements other than statements of historical fact contained in this press release are forward-looking statements. These forward-looking statements are not promises or guarantees and involve substantial risks and uncertainties. A further list and description of these risks, uncertainties and other risks associated with an investment in Amarin can be found in Amarin's filings with the U.S. Securities and Exchange Commission, including Amarin’s annual report on Form 10-K for the fiscal year ended 2025. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they are made. Amarin undertakes no obligation to update or revise the information contained in its forward-looking statements, whether as a result of new information, future events or circumstances or otherwise. Amarin’s forward-looking statements do not reflect the potential impact of significant transactions the company may enter into, such as mergers, acquisitions, dispositions, joint ventures or any material agreements that Amarin may enter into, amend or terminate. Investors and others should note that Amarin communicates with its investors and the public using the company website ( www.amarincorp.com ), the investor relations website ( www.amarincorp.com/investor-relations ), including but not limited to investor presentations and investor FAQs, U.S. Securities and Exchange Commission filings, press releases, public conference calls and webcasts.

Amarin Contact Information Media Inquiries: Tegan Berry Amarin Corporation plc PR@amarincorp.com

Investor Inquiries: Devin Sullivan & Conor Rodriguez The Equity Group on Behalf of Amarin devin.sullivan.ext@amarincorp.com or conor.rodriguez.ext@amarincorp.com Investor.relations@amarincorp.com

_____________________________________________ i Michael Szarek, Deepak L Bhatt, Michael Miller, Eliot A Brinton, Jean-Claude Tardif, Christie M Ballantyne, Steven B Ketchum, Mandeep R Mehra, Ph Gabriel Steg, on behalf of the REDUCE-IT Investigators, Effects of icosapent ethyl on risk and duration of hospitalizations and death in REDUCE-IT, European Journal of Preventive Cardiology , 2026;, zwag040, https://doi.org/10.1093/eurjpc/zwag040 ii Miller M, Tokgozoglu L, Parhofer KG, Handelsman Y, Leiter LA, Landmesser U, Brinton EA, Catapano AL. Icosapent ethyl for reduction of persistent cardiovascular risk: a critical review of major medical society guidelines and statements. Exp Rev Cardiovasc Ther . 2022;20:609-625. https://www.tandfonline.com/doi/full/10.1080/14779072.2022.2103541 iii Bhatt DL, Steg PG, Brinton E, et al., on behalf of the REDUCE-IT Investigators. Rationale and Design of REDUCE‐IT: Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial. Clin Cardiol. 2017;40:138-148. iv Bhatt DL, Steg PG, Miller M, et al., on behalf of the REDUCE-IT Investigators. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. N Engl J Med. 2019;380:11-22. v Bhatt DL, Steg PG, Miller M, et al., on behalf of the REDUCE-IT Investigators. Effects of Icosapent Ethyl on Total Ischemic Events: From REDUCE-IT. J Am Coll Cardiol. 2019;73:2791-2802. vi American Heart Association. Heart Disease and Stroke Statistics—2020 Update: A Report From the American Heart Association. Circulation. 2020;141:e139-e596. vii Ganda OP, Bhatt DL, Mason RP, et al. Unmet need for adjunctive dyslipidemia therapy in hypertriglyceridemia management. J Am Coll Cardiol. 2018;72(3):330-343. viii Budoff M. Triglycerides and triglyceride-rich lipoproteins in the causal pathway of cardiovascular disease. Am J Cardiol. 2016;118:138-145. ix Toth PP, Granowitz C, Hull M, et al. High triglycerides are associated with increased cardiovascular events, medical costs, and resource use: A real-world administrative claims analysis of statin-treated patients with high residual cardiovascular risk. J Am Heart Assoc. 2018;7(15):e008740. x Nordestgaard BG. Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease - New insights from epidemiology, genetics, and biology. Circ Res. 2016;118:547-563
## Recent Company News
- 2026-07-15 12:00 EST — [Amarin to Report Second Quarter 2026 Financial Results and Host Conference Call on July 29, 2026](https://biopharmsignal.com/news/AMRN/amarin-to-report-second-quarter-2026-financial-results-and-host-conference-call--e5f8b443) — Source: Amarin Corporation
- 2026-06-30 20:15 EST — [Amarin Reaffirms the Proven, Guideline-Recommended Role of VASCEPA® (Icosapent Ethyl) in an Evolving Triglyceride Treatment Landscape](https://biopharmsignal.com/news/AMRN/amarin-reaffirms-the-proven-guideline-recommended-role-of-vascepa-icosapent-ethy-d4f2d021) — Source: Amarin Corporation
- 2026-05-27 12:00 EST — [New REDUCE-IT® Analysis Presented at the European Atherosclerosis Society (EAS) Congress 2026 Suggests Risk-Weighted ApoB May Improve Identification of Residual Cardiovascular Risk in Statin-Treated Patients with Hypertriglyceridemia](https://biopharmsignal.com/news/AMRN/new-reduce-it-analysis-presented-at-the-european-atherosclerosis-society-eas-con-932ee205) — Source: Amarin Corporation
- 2026-04-29 11:00 EST — [Amarin Reports 2026 First Quarter Financial Results](https://biopharmsignal.com/news/AMRN/amarin-reports-2026-first-quarter-financial-results-56ba780b) — Source: Amarin Corporation
- 2026-04-15 12:00 EST — [Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026](https://biopharmsignal.com/news/AMRN/amarin-to-report-first-quarter-2026-financial-results-and-host-conference-call-o-65f0bc9f) — Source: Amarin Corporation
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)